These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 25901678)

  • 1. Cancer: An essential passenger with p53.
    Bradner JE
    Nature; 2015 Apr; 520(7549):626-7. PubMed ID: 25901678
    [No Abstract]   [Full Text] [Related]  

  • 2. Colorectal cancer: A circuitous way to target p53.
    Seton-Rogers S
    Nat Rev Cancer; 2015 Jun; 15(6):318-9. PubMed ID: 25971675
    [No Abstract]   [Full Text] [Related]  

  • 3. Colorectal cancer: POLR2A deletion with TP53 opens a window of opportunity for therapy.
    Errico A
    Nat Rev Clin Oncol; 2015 Jul; 12(7):374. PubMed ID: 25985938
    [No Abstract]   [Full Text] [Related]  

  • 4. TP53 loss creates therapeutic vulnerability in colorectal cancer.
    Liu Y; Zhang X; Han C; Wan G; Huang X; Ivan C; Jiang D; Rodriguez-Aguayo C; Lopez-Berestein G; Rao PH; Maru DM; Pahl A; He X; Sood AK; Ellis LM; Anderl J; Lu X
    Nature; 2015 Apr; 520(7549):697-701. PubMed ID: 25901683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new way to target p53-defective colorectal cancer.
    Liu Y; Wang L; Lu X
    Future Oncol; 2015; 11(23):3101-4. PubMed ID: 26549592
    [No Abstract]   [Full Text] [Related]  

  • 6. [p53 and Rb, clinical and therapeutic perspectives].
    Soussi T; Caron de Fromentel C
    Pathol Biol (Paris); 1993 Jan; 41(1):25-6. PubMed ID: 8316455
    [No Abstract]   [Full Text] [Related]  

  • 7. [Expression of phosphoprotein P53 in pathology].
    Casazza S
    Pathologica; 1993; 85(1097):321-34. PubMed ID: 8233649
    [No Abstract]   [Full Text] [Related]  

  • 8. Over-expression of p53 protein in neoplastic changes in ulcerative colitis: immunohistochemical study.
    Ajioka Y; Watanabe H; Matsuda K
    J Gastroenterol; 1995 Nov; 30 Suppl 8():33-5. PubMed ID: 8563884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The expression of mutation p53 gene from circulating cancer cells of peripheral blood and the clinical significance in detecting the patients with colorectal cancer].
    Ma GJ; Zhou JN; Shen ZL; Chen SQ; Zhu YQ; Wu XL; Xue KX
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):186-8. PubMed ID: 16604493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial and nutritional risk factors for p53 overexpression in colorectal cancer.
    Freedman AN; Michalek AM; Marshall JR; Mettlin CJ; Petrelli NJ; Black JD; Zhang ZF; Satchidanand S; Asirwatham JE
    Cancer Epidemiol Biomarkers Prev; 1996 Apr; 5(4):285-91. PubMed ID: 8722220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal p53 immunohistochemistry is associated with an increased colorectal cancer-related mortality in patients with ulcerative colitis.
    Lashner BA; Bauer WM; Rybicki LA; Goldblum JR
    Am J Gastroenterol; 2003 Jun; 98(6):1423-7. PubMed ID: 12818291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases.
    Sturm I; Köhne CH; Wolff G; Petrowsky H; Hillebrand T; Hauptmann S; Lorenz M; Dörken B; Daniel PT
    J Clin Oncol; 1999 May; 17(5):1364-74. PubMed ID: 10334520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53 abnormalities and outcomes in colorectal cancer: a systematic review.
    Smith FM; Stephens RB; Kennedy MJ; Reynolds JV
    Br J Cancer; 2005 May; 92(9):1813. PubMed ID: 15856032
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.
    Akkiprik M; Ataizi-Celikel C; Düşünceli F; Sönmez O; Gulluoglu BM; Sav A; Ozer A
    J Gastrointestin Liver Dis; 2007 Mar; 16(1):11-7. PubMed ID: 17410283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent p53 mutation in brain (fetal)-type glycogen phosphorylase positive foci adjacent to human 'de novo' colorectal carcinomas.
    Shimada S; Shiomori K; Tashima S; Tsuruta J; Ogawa M
    Br J Cancer; 2001 Jun; 84(11):1497-504. PubMed ID: 11384100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Have p53 gene mutations and protein expression a different biological significance in colorectal cancer?
    Bazan V; Migliavacca M; Tubiolo C; Macaluso M; Zanna I; Corsale S; Amato A; Calò V; Dardanoni G; Morello V; La Farina M; Albanese I; Tomasino RM; Gebbia N; Russo A
    J Cell Physiol; 2002 May; 191(2):237-46. PubMed ID: 12064467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer.
    Spitz FR; Nguyen D; Skibber JM; Cusack J; Roth JA; Cristiano RJ
    Anticancer Res; 1996; 16(6B):3415-22. PubMed ID: 9042200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tumor suppressor genes in cancers of colon and rectum].
    Thomas G; Olschwang S; Laurent-Puig P
    Rev Prat; 1991 Nov; 41(23):2313-5. PubMed ID: 1792493
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunohistochemical detection of p53 tumor suppressor gene protein in canine epithelial colorectal tumors.
    Wolf JC; Ginn PE; Homer B; Fox LE; Kurzman ID
    Vet Pathol; 1997 Sep; 34(5):394-404. PubMed ID: 9381650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stalking the guardian of the genome: p53 in colorectal carcinogenesis.
    Ahnen DJ
    Am J Gastroenterol; 1996 Jan; 91(1):3-6. PubMed ID: 8561139
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.